Warburg Micro Syndrome 3 (WARBM3) Cell Models for Research

Warburg Micro Syndrome 3 (WARBM3) is an ultra-rare autosomal recessive neurodevelopmental disorder. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals worldwide. The condition is characterized by microcephaly, intellectual disability, optic atrophy, and congenital malformations. There is no cure, and management is supportive. The disease is caused by mutations in the RAB3GAP2 gene, which plays a role in vesicle trafficking and autophagy. Research is crucial to understand the molecular mechanisms and develop potential therapies.

WARBM3 serves as an excellent model for studying neurodevelopmental pathways, particularly those involving RAB3GAP2 and its interacting partners. The disease's monogenic nature allows for precise genetic manipulation in cell models. Key research questions include: How do RAB3GAP2 mutations disrupt neuronal development? What are the downstream effects on synaptic function? Can we identify therapeutic targets to rescue the phenotype? Gene-edited cell models provide a controlled system to answer these questions.

The primary pathway involves RAB3GAP2, a catalytic subunit of the Rab3GAP complex, which regulates Rab3 GTPase activity essential for calcium-dependent exocytosis of neurotransmitters. Mutations lead to impaired vesicle trafficking and autophagy. Key steps:

1. RAB3GAP2 mutations cause loss of function.

2. Rab3 activity is dysregulated, affecting synaptic vesicle release.

3. Autophagy flux is impaired, leading to accumulation of damaged organelles.

4. Neuronal development and survival are compromised, resulting in microcephaly and intellectual disability.

Data from ClinVar and UniProt indicate that most pathogenic variants are loss-of-function.

Key networks affected include:

• • Vesicle trafficking: RAB3, RAB27, and other Rab GTPases.
• • Autophagy: mTOR pathway, LC3 lipidation.
• • Neuronal survival: PI3K/AKT and MAPK pathways.

Disruption of these networks leads to synaptic dysfunction and neurodegeneration.

Organoids, such as cerebral organoids, provide a 3D model to study neurodevelopmental defects.

• • Rab3gap2 knockout mice: exhibit microcephaly and impaired synaptic function.
• • Zebrafish models: used for high-throughput drug screening.
• • Drosophila models: to study conserved pathways.

These models are valuable for in vivo validation.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise RAB3GAP2 mutations. For example:

• • RAB3GAP2 knockout lines: complete loss of function.
• • RAB3GAP2 point mutation knock-in lines: mimic patient-specific mutations.

These models are commercially available and sequence-verified, accelerating research. They allow for controlled experiments to dissect molecular mechanisms and test therapeutic interventions.

Knockout and knock-in lines are used to validate the role of RAB3GAP2 in neuronal function. For example, RAB3GAP2 knockout SH-SY5Y cells show reduced neurite outgrowth and altered synaptic protein expression, confirming its role in neurodevelopment.

Isogenic pairs (wild-type vs. RAB3GAP2 knockout) are used to screen for compounds that rescue the phenotype. High-throughput screens can identify drugs that modulate autophagy or vesicle trafficking, potentially leading to therapeutic candidates.

CRISPR screens can identify synthetic lethal partners of RAB3GAP2 deficiency, revealing potential drug targets. Additionally, gene-edited cells can be used to discover biomarkers for disease progression or treatment response.